These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8557879)

  • 1. Imipenem/cilastin dosage during acute renal failure and hemofiltration.
    Dehne MG; Kroh UF
    Intensive Care Med; 1995 Oct; 21(10):863. PubMed ID: 8557879
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration.
    Przechera M; Bengel D; Risler T
    Contrib Nephrol; 1991; 93():131-4. PubMed ID: 1802563
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.
    Tegeder I; Bremer F; Oelkers R; Schobel H; Schüttler J; Brune K; Geisslinger G
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2640-5. PubMed ID: 9420033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration.
    Mueller BA; Scarim SK; Macias WL
    Am J Kidney Dis; 1993 Feb; 21(2):172-9. PubMed ID: 8430678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).
    Vos MC; Vincent HH; Yzerman EP
    Intensive Care Med; 1992; 18(5):282-5. PubMed ID: 1527259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using imipenem and cilastatin during continuous renal replacement therapy.
    Cotton A; Franklin BD; Brett S; Holmes A
    Pharm World Sci; 2005 Oct; 27(5):371-5. PubMed ID: 16341743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of imipenem-cilastatin in pediatrics.
    Overturf GD
    Pediatr Infect Dis J; 1989 Nov; 8(11):792-4. PubMed ID: 2687788
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of tularemia with imipenem/cilastatin sodium.
    Lee HC; Horowitz E; Linder W
    South Med J; 1991 Oct; 84(10):1277-8. PubMed ID: 1925735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration.
    Alarabi AA; Cars O; Danielson BG; Salmonson T; Wikström B
    J Antimicrob Chemother; 1990 Jul; 26(1):91-8. PubMed ID: 2211452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
    Keller E; Fecht H; Böhler J; Schollmeyer P
    Nephrol Dial Transplant; 1989; 4(7):640-5. PubMed ID: 2510062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants].
    Bégué P; Quinet B; Baron S; Challier P; Fontaine JL; Lasfargues G
    Pathol Biol (Paris); 1989 May; 37(5):485-90. PubMed ID: 2674874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.
    Balfour JA; Bryson HM; Brogden RN
    Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy during continuous arteriovenous hemofiltration.
    Keller E
    Adv Exp Med Biol; 1989; 260():117-27. PubMed ID: 2696363
    [No Abstract]   [Full Text] [Related]  

  • 15. [The clinical efficacy of imipenem/cilastatin sodium in orthopedic infections and drug levels in the bone tissue].
    Handa N; Kawakami T; Kitaoka K; Ueda E; Shinjou H; Shimizu T; Itou K; Iwakawa M; Yamamoto H; Ando M; Yamanaka N; Nakauchi M; Nieda T; Kondou M
    Jpn J Antibiot; 1997 Jul; 50(7):622-7. PubMed ID: 9743907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies.
    Janmohamed RM; Leyland MJ; Kelly J; Farrell I
    J Antimicrob Chemother; 1990 Mar; 25(3):407-12. PubMed ID: 2338419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbapenems in febrile neutropenic patients.
    Gaya H
    J Antimicrob Chemother; 1997 May; 39(5):667-8. PubMed ID: 9184371
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem.
    Fichtenbaum CJ; Smith MJ
    Clin Infect Dis; 1992 Jan; 14(1):353-4. PubMed ID: 1571451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration.
    Pea F; Brollo L; Lugano M; Dal Pos L; Furlanut M
    Ther Drug Monit; 2001 Oct; 23(5):587-8. PubMed ID: 11591906
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.
    Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H; Shiratori K; Ueda S; Takagi N; Umemura S; Shionoiri H
    Clin Nephrol; 1994 Sep; 42(3):193-7. PubMed ID: 7994939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.